The use of hyaluronic acid in vulvovaginal atrophy in women after antitumor therapy
Mkrtchian L.S., Kukosh M.Yu., Bychkova A.E., Apolikhina I.A., Ivanov S.A., Kaprin A.D., Zamulaeva I.A.
Objective: To analyze the available literature on the use of hyaluronic acid in programs of non-hormonal correction of vulvovaginal disorders associated with antitumor treatment in cancer patients.
Materials and methods: The literature search was conducted in the electronic databases, namely PubMed, Scopus, Web of Science, Cochrane Library, ScienceDirect, Embase, PsycINFO using the keywords in Russian and English. The articles were published between 1914 and 2024.
Results: The symptoms of genitourinary syndrome of menopause have a long-term negative impact on the quality of life of women who underwent antitumor treatment. Currently, it is important to develop approaches to supportive and restorative therapy for women at risk of developing genitourinary syndrome of menopause. One of the effective methods for correcting this condition in women undergoing oncological rehabilitation is the use of intravaginal preparations containing hyaluronic acid. These preparations significantly reduce the symptoms of vulvovaginal atrophy with efficacy comparable to that of topical estrogens. Besides, they have high safety and do not cause side effects.
Conclusion: The analysis of the literature showed the potential for further research into the efficacy and safety of using hyaluronic acid to correct vulvovaginal changes in cancer patients after antitumor therapy, as well as for long-term follow-up. This research could help determine whether it should be included in the standard restorative treatment for these patients. Such an approach could improve the quality of life for this patient group and address a number of psychological and socio-economic issues.
Authors’ contributions: Mkrtchian L.S. – developing the idea of the article and the concept of the review, writing the text, scientific editing, approval of the final version of the article; Kukosh M.Yu. – collection and analysis of scientific material on clinical research, writing the text; Apolikhina I.A. – analysis of the material, scientific editing; Bychkova A.E. – work with literature, writing the text, preparing the manuscript for publication; Ivanov S.A., Kaprin A.D. – scientific review of the text; Zamulaeva I.A. – collection and analysis of scientific material on fundamental research, writing the text, scientific review.
Conflicts of interest: Authors declare lack of the possible conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Mkrtchian L.S., Kukosh M.Yu., Bychkova A.E., Apolikhina I.A., Ivanov S.A., Kaprin A.D., Zamulaeva I.A. The use of hyaluronic acid in vulvovaginal atrophy in women after antitumor therapy.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (8): 26-35 (in Russian)
https://dx.doi.org/10.18565/aig.2025.191
Keywords
References
- Pérez-López F.R., Phillips N., Vieira-Baptista P., Cohen-Sacher B., Fialho S.C.A.V., Stockdale C.K. Management of postmenopausal vulvovaginal atrophy: recommendations of the International society for the study of vulvovaginal disease. Gynecol. Endocrinol. 2021; 37(8): 746-52.https://dx.doi.org/10.1080/09513590.2021.1943346
- Lev-Sagie A. Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. Clin. Obs. Gynecol. 2015; 58(3): 476-91. https://dx.doi.org/10.1097/GRF.0000000000000126
- Gliniewicz K., Schneider G.M., Ridenhour B.J., Williams C.J., Song Y., Farage M.A. et al. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. Front. Microbiol. 2019; 10: 193. https://dx.doi.org/10.3389/fmicb.2019.00193
- Brotman R.M., Shardell M.D., Gajer P., Fadrosh D., Chang K., Silver M.I. et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014; 21: 450-8. https://dx.doi.org/10.1097/GME.0b013e3182a4690b
- Nappi R.E., Cucinella L., Martini E., Cassani C. The role of hormone therapy in urogenital health after menopause. Best Pract. Res. Clin. Endocrinol. Metab. 2021; 35: 101595. https://dx.doi.org/10.1016/j.beem.2021.101595
- Escobar C., Rosenblum N. Vaginal estrogen-what a urologist should know. Urology. 2021; 151: 37-43. https://dx.doi.org/10.1016/j.urology.2020.05.034
- Cox P., Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019; 22(6): 565-71. https://dx.doi.org/10.1080/13697137.2019.1643180
- The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020; 27(9): 976-92. https://dx.doi.org/10.1097/GME.0000000000001609
- Gambacciani M. Managing vulvovaginal atrophy after breast cancer. Post Reprod. Health. 2019; 25(3): 167-8. https://dx.doi.org/10.1177/2053369119848884
- Meriggiola M.C., Villa P., Maffei S., Becorpi A., Di Paolantonio T., Nicolucci A. et al. Vulvovaginal atrophy in women with and without a history of breast cancer: baseline data from the Patient satisfaction study (PEONY) in Italy. Maturitas. 2024; 183: 107950. https://dx.doi.org/10.1016/j.maturitas.2024.107950
- Guidozzi F. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. Climacteric. 2016; 19(5): 419-22. https://dx.doi.org/10.1080/13697137.2016.1209396
- Kelsey T.W., Hua C.H., Wyatt A., Indelicato D., Wallace W.H. A predictive model of the effect of therapeutic radiation on the human ovary. PLOS One. 2022; 17(11): e0277052. https://dx.doi.org/10.1371/journal.pone.0277052
- Huang Y., Qin T., Yang M., Liu Z. Impact of ovary-sparing treatment planning on plan quality, treatment time and gamma passing rates in intensity-modulated radiotherapy for stage I/II cervical cancer. Medicine (Baltimore). 2023; 102(50): e36373. https://dx.doi.org/10.1097/MD.0000000000036373
- Moss E.L., Taneja S., Munir F., Kent C., Robinson L., Potdar N. et al. Iatrogenic menopause after treatment for cervical cancer. Clin. Oncol. (R. Coll. Radiol.). 2016; 28(12): 766-75. https://dx.doi.org/10.1016/j.clon.2016.08.016
- Panay N., Fenton A. Iatrogenic menopause following gynecological malignancy: time for action! Climacteric. 2016; 19(1): 1-2. https://dx.doi.org/10.3109/13697137.2015.1127640
- Kollberg K.S., Waldenström A.-C., Bergmark K., Dunberger G., Rossander A., Wilderäng U. et al. Reduced vaginal elasticity, reduced lubrication, and deep and superficial dyspareunia in irradiated gynecological cancer survivors. Acta Oncol. 2015; 54(5): 772-9. https://dx.doi.org/10.3109/0284186X.2014.1001036
- Jensen P.T., Froeding L.P. Pelvic radiotherapy and sexual function in women. Transl. Androl. Urol. 2015; 4(2): 186-205. https://dx.doi.org/10.3978/j.issn.2223-4683.2015.04.06
- Джанашвили Л.Г., Назаренко Т.А., Балахонцева О.С., Мартиросян Я.О., Пронин С.М., Калинина Е.А., Бирюков А.М. Реализация репродуктивной функции у больных с атипической гиперплазией и раком эндометрия I стадии. Акушерство и гинекология. 2020; 4: 45-51. [Dzhanashvili L.G., Nazarenko T.A., Balakhontseva O.S., Martirosyan Ya.O., Pronin S.M., Kalinina E.A., Biryukova A.M. Realization of reproductive potential in patients with atypical hyperplasia and stage I endometrial cancer. Obstetrics and Gynecology. 2020; (4): 45-51 (in Russian)]. https://dx.doi.org/10.18565/aig.2020.4.45-51
- Кутаков Н.М., Чекини Д.А. Перспективы и возможности сохранения репродуктивной функции у больных, получающих противоопухолевое лечение. Клиническое наблюдение. MD-Onco. 2023; 3(2): 16-9. [Kutakov N.M., Chekini D.A. Perspectives and possibilities of preserving reproductive function in patients receiving antitumor treatment. Clinical observation. MD-Onco. 2023; 3(2): 16-9 (in Russian)]. https://dx.doi.org/10.17650/ 2782-3202-2023-3-2-16-19
- Назаренко Т.А., Сухих Г.Т., ред. Сохранение репродуктивной функции онкологических больных. Руководство для врачей. М.: МЕДпресс-информ; 2022. 160 с. [Nazarenko T.A., Sukhikh G.T., eds. Preservation of reproductive function in cancer patients. Manual for physicians. Moscow: MEDpress-Inform; 2022. 160 p. (in Russian)].
- Claes M., Tuts L., Robijns J., Mulders K., Van De Werf E., Bulens P. et al. Cancer therapy-related vaginal toxicity: its prevalence and assessment methods – a systematic review. J. Cancer Surviv. 2024; 19: 1293-312. https://dx.doi.org/10.1007/s11764-024-01553-y
- Cotangco K., Class Q.A., Johnson T.P., Kothari R. Cervical cancer survivors’ attitudes and understanding of menopause and hormone therapy. Menopause. 2020; 27(6): 701-5. https://dx.doi.org/10.1097/GME.0000000000001520
- Hofsjö A., Bergmark K., Blomgren B., Jahren H., Bohm-Starke N. Radiotherapy for cervical cancer – impact on the vaginal epithelium and sexual function. Acta Oncol. 2018; 57(3): 338-45. https://dx.doi.org/10.1080/0284186X.2017.1400684
- Tramacere F., Lancellotta V., Casà C., Fionda B., Cornacchione P., Mazzarella C. et al. Assessment of sexual dysfunction in cervical cancer patients after different treatment modality: a systematic review. Medicina (Kaunas). 2022; 58(9): 1223. https://doi.org/10.3390/medicina58091223
- Kirchheiner K., Smet S., Jürgenliemk-Schulz I.M., Haie-Meder C., Chargari C., Lindegaard J.C. et al. Impact of vaginal symptoms and hormonal replacement therapy on sexual outcomes after definitive chemoradiotherapy in patients with locally advanced cervical cancer: results from the EMBRACE-I study. Int. J. Radiat. Oncol. Biol. Phys. 2022; 112(2): 400-13. https://doi.org/10.1016/j.ijrobp.2021.08.036
- Мкртчян Л.С., Иванов С.А., Кулиева Г.З.К., Замулаева И.А., Крикунова Л.И. Улучшение качества жизни больных раком шейки матки после лучевой т химиолучевой терапии. Радиация и риск (Бюллетень НРЭР). 2020; 1(29): 120-8. [Mkrtchian L.S., Ivanov S.A., Kulieva G.Z.K., Zamulaeva I.A., Krikunova L.I. Quality of life of patients with cervical cancer after radiotherapy and chemoradiotherapy. Radiation and risk. 2020; 1(29): 120-8 (in Russian)]. https://dx.doi.org/10.21870/0131-3878-2020-29-1-120-128
- Rees M., Angioli R., Coleman R.L., Glasspool R., Plotti F., Simoncini T. et al. European menopause and andropause society (EMAS) and International gynecologic cancer society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020; 134: 56-61. https://dx.doi.org/10.1016/j.maturitas.2020.01.005
- Filippini M., Porcari I., Ruffolo A.F., Casiraghi A., Farinelli M., Uccella S. et al. CO2-Laser therapy and genitourinary syndrome of menopause: a systematic review and meta-analysis. J. Sex. Med. 2022; 19(3): 452-70. https://dx.doi.org/10.1016/j.jsxm.2021.12.010
- Benini V., Ruffolo A.F., Casiraghi A., Degliuomini R.S., Frigerio M., Braga A. et al. New innovations for the treatment of vulvovaginal atrophy: an up-to-date review. Medicina (Kaunas). 2022; 58(6): 770. https://dx.doi.org/10.3390/medicina58060770
- Desai S.A., Kroumpouzos G., Sadick N. Vaginal rejuvenation: from scalpel to wands. Int. J. Womens Dermatol. 2019; 5(2): 79-84. https://dx.doi.org/10.1016/j.ijwd.2019.02.003
- Cox P., Panay N. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause. Climacteric. 2023; 26(4): 367-72. https://dx.doi.org/10.1080/13697137.2023.2210283
- Woopen H., Sehouli J., Davis A., Lee Y.C. , Cohen P.A., Ferrero A. et al. GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: a position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. Cancer Treat. Rev. 2022; 107: 102396. https://dx.doi.org/10.1016/j.ctrv.2022.102396
- Faubion S.S., Larkin L.C., Stuenkel C.A., Bachmann G.A., Chism L.A., Kagan R. et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018; 25(6): 596-608. https://dx.doi.org/10.1097/GME.0000000000001121
- Kuhle C.L., Kapoor E., Sood R., Thielen J.M., Jatoi A., Faubion S.S. Menopausal hormone therapy in cancer survivors: a narrative review of the literature. Maturitas. 2016; 92: 86-96. https://dx.doi.org/10.1016/j.maturitas.2016.07.018
- Sassarini J., Perera M., Spowart K., McAllister K., Fraser J., Glasspool R. et al. Managing vulvovaginal atrophy after breast cancer. Post Reprod. Health. 2018; 24(4): 163-5. https://dx.doi.org/10.1177/2053369118805344
- Министерство здравоохранения Российской Федерация. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. М.; 2024. 93 с. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and menopause in women. Moscow; 2024. 93 p. (in Russian)].
- Marès P., Jauffret C., Martin C., Lopes P., Coussy F. Genitourinary syndrome of menopause in patients with breast cancer treated by hormonotherapy: women's perception in ITAC, a French web-based survey. Bull. Cancer. 2024; 111(4): 347-55. https://dx.doi.org/10.1016/j.bulcan.2023.08.014
- Pruthi S., Simon J.A., Early A.P. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J. 2011; 17(4): 403-8. https://dx.doi.org/10.1111/j.1524-4741.2011.01089.x
- Faubion S.S., Larkin L.C., Stuenkel C.A., Bachmann G.A., Chism L.A., Kagan R. et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018; 25(6): 596-608. https://dx.doi.org/10.1097/GME.0000000000001121
- Concin N., Matias-Guiu X., Vergote I., Cibula D., Mirza M.R., Marnitz S. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer. 2021; 31(1): 12-39. https://dx.doi.org/10.1136/ijgc-2020-002230
- Chargari C., Tanderup K., Planchamp F., Chiva L., Humphrey P., Sturdza A. et al. ESGO / ESTRO quality indicators for radiation therapy of cervical cancer. Int. J. Gynecol. Cancer. 2023; 33(6): 862-75. https://dx.doi.org/10.1136/ijgc-2022-004180
- Dicker K.T., Gurski L.A., Pradhan-Bhatt S., Witt R.L., Farach-Carson M.C., Jia X. Hyaluronan: a simple polysaccharide with diverse biological functions. Acta Biomater. 2014; 10(4): 1558-70. https://dx.doi.org/10.1016/j.actbio.2013.12.019
- Al Ghanim K., Jaszkul K.M., Simpson A., Turley E.A. Association of squamous cell carcinoma and hyaluronan: a scope of the literature. Eplasty. 2024; 24: e11.
- Tavianatou A.G., Caon I., Franchi M., Piperigkou Z., Galesso D., Karamanos N.K. Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer. FEBS J. 2019; 286(15): 2883-2908. https://dx.doi.org/10.1111/febs.14777
- Fallacara A., Baldini E., Manfredini S., Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018; 10(7): 701. https://dx.doi.org/10.3390/polym10070701
- Garantziotis S., Savani R.C. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 2019; 78-79: 1-10. https://dx.doi.org/10.1016/j.matbio.2019.02.002
- Parnigoni A., Moretto P., Rovera S., Viola M., Karousou E., Passi A. et al. Particle exclusion assay: a tool for measuring hyaluronan pericellular matrix. Methods Mol. Biol. 2023; 2619: 53-60. https://dx.doi.org/10.1007/978-1-0716-2946-8_4
- Tolg C., Messam B.J., McCarthy J.B., Nelson A.C., Turley E.A. Hyaluronan functions in wound repair that are captured to fuel breast cancer progression. Biomolecules. 2021; 11(11): 1551. https://dx.doi.org/10.3390/biom11111551
- Price Z.K., Lokman N.A., Ricciardelli C. Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers (Basel). 2018; 10(12): 482. https://dx.doi.org/10.3390/cancers10120482
- Albtoush N., Queisser K.A., Zawerton A., Lauer M.E., Beswick E.J., Petrey A.C. TSG6 hyaluronan matrix remodeling dampens the inflammatory response during colitis. Matrix Biol. 2023; 121: 149-66. https://dx.doi.org/10.1016/j.matbio.2023.06.007
- Triggs-Raine B., Natowicz M.R. Biology of hyaluronan: insights from genetic disorders of hyaluronan metabolism. World J. Biol. Chem. 2015; 6(3): 110-20. https://dx.doi.org/10.4331/wjbc.v6.i3.110
- Шнайдер Н.А., Дюжакова А.В., Вайман Е.Э., Никитина Е.И., Борзых О.Б., Насырова Р.Ф. Значение генетических факторов метаболизма эндогенной гиалуроновой кислоты в поддержании гомеостаза кожи. Вестник дерматологии и венерологии. 2021; 97(3): 24-38. [Shnayder N.A., Dyuzhakova A.V., Vaiman E.E., Nikitina E.I., Borzykh O.B., Nasyrova R.F. The role of genetic factors of endogenous hyaluronic acid metabolism in maintaining skin homeostasis. Vestnik dermatologii i venerologii. 2021; 97(3): 24-38 (in Russian)]. https://dx.doi.org/10.25208/vdv1193
- Kobayashi T., Chanmee T., Itano N. Hyaluronan: metabolism and function. Biomolecules. 2020; 10(11): 1525. https://dx.doi.org/10.3390/biom10111525
- Cirillo N. The hyaluronan/CD44 axis: a double-edged sword in cancer. Int. J. Mol. Sci. 2023; 24(21): 15812. https://dx.doi.org/10.3390/ijms242115812
- Матчук О.Н., Замулаева И.А. Количественные изменения популяции стволовых клеток рака шейки матки линии Hela под влиянием фракционированного γ-облучения in vitro. Радиация и риск. 2019; 28(2): 112-23. [Matchuk O.N., Zamulaeva I.A. Quantitative changes in the stem cell population of cervical cancer cell line HeLa under the influence of fractionated γ-irradiation in vitro. Radiation and risk. 2019; 28(2): 112-23 (in Russian)]. https://dx.doi.org/10.21870/0131-3878-2019-28-2-112-123
- Замулаева И.А., Матчук О.Н., Селиванова Е.И., Андреев В.Г., Липунов Н.М., Макаренко С.А., Жаворонков Л.П., Саенко А.С. Увеличение количества опухолевых стволовых клеток под воздействием редкоионизирующего излучения. Радиационная биология. Радиоэкология. 2014; 54(3): 256-64. [Zamulaeva I.A., Matchuk O.N., Selivanova E.I., Andreev V.G., Lipunov N.M., Makarenko S.A., Zhavoronkov L.P., Saenko A.S. Increase in the number of cancer stem cells after exposure to low-LET radiation. Radiats Biol. Radioecol. 2014; 54(3): 256-64 (in Russian)]. https://dx.doi.org/10.7868/S0869803114030187
- Peitzch C., Kurth I., Ebert N., Dubrovska A., Baumann M. Cancer stem cells in radiation response: current views and future perspectives in radiation oncology. Int. J. Radiat. Biol. 2019; 95(7): 900-11. https://dx.doi.org/10.1080/09553002.2019.1589023
- Phi L., Sari I., Yang Y.-G., Lee S.-H., Jun N., Kim K.S. et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018; 2018: 5416923. https://dx.doi.org/10.1155/2018/5416923
- Zamulaeva I.A., Selivanova E.I., Matchuk O.N., Krikunova L.I., Mkrtchyan L.S., Kulieva G.Z. et al. Quantitative changes in the population of cancer stem cells after radiation exposure in a dose of 10 gy as a prognostic marker of immediate results of the treatment of squamous cell cervical cancer. Bull. Exp. Biol. Med. 2019; 168(1): 156-9. https://dx.doi.org/10.1007/s10517-019-04667-x
- Zamulaeva I., Matchuk O., Selivanova E., Mkrtchian L., Yakimova A., Gusarova V. et al. Effects of fractionated radiation exposure on vimentin expression in cervical cancers: analysis of association with cancer stem cell response and short-term prognosis. Int. J. Mol. Sci. 2023; 24(4): 3271. https://dx.doi.org/10.3390/ijms24043271
- Lytle N.K., Barber A.G., Reya T. Stem cells fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer. 2018; 18(11): 669-80. https://dx.doi.org/10.1038/s41568-018-0056-x
- Palomeras S., Ruiz-Martínez S., Puig T. Targeting breast cancer stem cells to overcome treatment resistance. Molecules. 2018; 23(9): 2193. https://dx.doi.org/10.3390/molecules23092193
- Luo M., Clouthier S.G., Deol Y., Liu S., Nagrath S., Azizi E. et al. Breast cancer stem cells: current advances and clinical implications. Methods Mol Biol. 2015; 1293: 1-49. https://dx.doi.org/10.1007/978-1-4939-2519-3_1
- Yang F., Xu J., Tang L., Guan X. Breast cancer stem cell: the roles and therapeutic implications. Cell. Mol. Life Sci. 2017; 74(6): 951-66. https://dx.doi.org/10.1007/s00018-016-2334-7
- Chanmee T., Ontong P., Kimata K., Itano N. Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells. Front. Oncol. 2015; 5: 180. https://dx.doi.org/10.3389/fonc.2015.00180
- Bourguignon L.Y.W., Shiina M., Li J.J. Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. Adv. Cancer Res. 2014; 123: 255-75. https://dx.doi.org/10.1016/B978-0-12-800092-2.00010-1
- Киселёва М.В., Замулаева И.А., Радзинский В.Е., Оразов М.Р., Долгов Е.Д., Иванов С.А., Каприн А.Д. Новый метод лечения вульвовагинальной атрофии у пациенток с отягощенным онкологическим анамнезом. Вопросы гинекологии, акушерства и перинатологии. 2024; 23(3):111-7. [Kiseleva M.V., Zamulaeva I.A., Radzinsky V.E., Orazov M.R., Dolgov E.D., Ivanov S.A., Kaprin A.D. New therapeutic approach to vulvovaginal atrophy in patients with a history of cancer. Gynecology, Obstetrics and Perinatology. 2024; 23(3): 111-7 (in Russian)]. https://dx.doi.org/10.20953/1726-1678-2024-3-111-117
- Liu Z., Hou P., Fang J., Shao C., Shi Y., Melino G. et al. Hyaluronic acid metabolism and chemotherapy resistance: recent advances and therapeutic potential. Mol. Oncol. 2024; 18(9): 2087-2106. https://dx.doi.org/10.1002/1878-0261.13551
- Bourguignon L.Y.W., Earle C., Shiina M. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance. Matrix Biol. 2019; 78-79: 180-200.https://dx.doi.org/10.1016/j.matbio.2018.07.008
- Cascone S., Lamberti G. Hydrogel-based commercial products for biomedical applications: a review. Int. J. Pharm. 2020; 573: 118803. https://dx.doi.org/10.1016/j.ijpharm.2019.118803
Received 15.07.2025
Accepted 13.08.2025
About the Authors
Liana S. Mkrtchian, Dr. Med. Sci., Head of the Department of Medical Rehabilitation and Rehabilitation Technologies, A.F. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia; Professor, Department of Obstetrics and Gynecology, Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University «MEPhI», 249036, Russia, Kaluga Region, Obninsk, Koroleva str., 4, liana6969@mail.ru,https://orcid.org/0000-0002-5027-5331
Marina Yu. Kukosh, PhD, Senior Researcher at the Department of Medical Rehabilitation and Rehabilitation Technologies, A.F. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia; Associate Professor, Department of Oncology and Hematology, Medical Institute, P. Lumumba RUDN University, 249036, Russia, Kaluga Region, Obninsk, Koroleva str., 4, manja70@inbox.ru, https://orcid.org/0000-0001-6481-1724
Anastasia E. Bychkova, obstetrician-gynecologist, oncologist at the Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; PhD student, A.F. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparin str., 4, a_bychkova88@mail.ru, https://orcid.org/0000-0003-4855-8188
Inna A. Apolikhina, Dr. Med. Sci., Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparin str., 4; Professor, Department of Obstetrics, Gynecology, Perinatology and Reproductology, Institute of Vocational Education, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), 119048, Russia, Moscow, Trubetskaya str., 8, bld. 2, i_apolikhina@oparina4.ru, https://orcid.org/0000-0002-4581-6295
Sergey A. Ivanov, Dr. Med. Sci., Corresponding Member of the RAS, Director, A.F. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia; Professor, Department of Oncology and Radiology named after V.P. Kharchenko of Medical Institute, P. Lumumba
RUDN University, 249036, Russia, Kaluga Region, Obninsk, Koroleva str., 4, oncourolog@gmail.com, https://orcid.org/0000-0001-7689-6032
Andrey D. Kaprin, Dr. Med. Sci., Professor, Academician of the RAS, Academician of the Russian Academy of Education, Director, P. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre, Ministry of Health of Russia; Director General, National Medical Research Center of Radiology, Ministry of Health of Russia; Head of the Department of Oncology and Radiology named after V.P. Kharchenko of the Medical Institute, P. Lumumba RUDN University, 249036, Russia, Kaluga Region, Obninsk, Koroleva str., 4, kaprin@mail.ru, https://orcid.org/0000-0001-8784-8415
Irina A. Zamulaeva, Dr. Sci. (Bio), Professor, Head of the Department of Radiation Biochemistry, A.F. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 249036, Russia, Kaluga Region, Obninsk, Koroleva str., 4, zamulaeva@mail.ru,
https://orcid.org/0000-0002-6136-8445
Corresponding author: Liana S. Mkrtchian, liana.mko@gmail.com